To Get Full Access :

NCE-1 Intelligence & Market Opportunity

Ojjaara

Momelotinib
Anticancer
Tablet

Ojjaara is an oral medication for adults with intermediate or high-risk myelofibrosis and anemia. It targets JAK1, JAK2, and ACVR1 to reduce spleen size, relieve symptoms, and improve anemia.

Approval Date
15-Sep-23
NCE-1 Date
15-Sep-27
NCE Date
15-Sep-28
Commercial snapshot

Market performance & projections

Revenue ($M)
730
CAGR (%)
16.38%
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
976
2027
1,166
2028
1,264
2029
1,339
2030
1,407
2031
1,476
2032
1,543
Molecule profile

Details & specifications

Molecule
Momelotinib
Innovator
GLAXOSMITHKLINE LLC
Dosage Form
Tablet
Strength
100 mg, 150 mg and 200 mg
Therapeutic Category
Anticancer
Usage
To treat intermediate or high-risk myelofibrosis in adults with anemia
Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?